Case Overview

The Parties

The Patents at Issue

This case involved two U.S. patents covering innovations in cfDNA-based testing methodologies, specifically technologies enabling the detection of minimal residual disease. These patents are critical for tumor-informed genomic sequencing in post-treatment cancer monitoring.

• • US11530454B2 — cfDNA-based testing methodologies
• • US11519035B2 — Technologies for minimal residual disease detection

The Verdict & Legal Analysis

Outcome

The Federal Circuit **affirmed** the district court’s grant of Natera’s preliminary injunction. NeoGenomics’ appeal was dismissed, and the injunction against its cfDNA-based testing product remained in force. No specific damages award was associated with this appellate proceeding, as the matter concerned injunctive—not compensatory—relief at this stage.

Key Legal Issues

The Federal Circuit reviewed the preliminary injunction under the **abuse of discretion standard**, one of the most deferential standards in appellate review. The court found NeoGenomics failed to demonstrate that the district court abused its discretion on any of the four preliminary injunction prongs: (1) likelihood of success on the merits, (2) likelihood of irreparable harm, (3) balance of hardships, and (4) public interest. The appellate panel specifically noted that NeoGenomics’ remaining arguments were “unpersuasive,” affirming the district court’s balanced and thorough analysis.

Judicial Commentary on Litigation Conduct

A particularly notable element of this decision is the Federal Circuit’s endorsement of the district court’s critique of both parties’ “kitchen-sink” litigation approach. This judicial commentary carries strategic significance: courts in technically complex patent matters—particularly emerging biotechnology areas like cfDNA diagnostics—are explicitly signaling intolerance for argument overloading. Counsel on both sides in future cfDNA patent infringement cases should anticipate that precision, not volume, is what courts reward.

Public Interest Balancing

The district court’s explicit effort to minimize the preliminary injunction’s “negative impact on the public interest” is legally significant. In healthcare patent disputes, public interest weighing often tilts toward denying injunctions that would restrict patient access to diagnostics. The fact that the district court structured the injunction carefully—and that the Federal Circuit affirmed it—suggests Natera’s likelihood-of-success showing was sufficiently strong to overcome this typically formidable hurdle in medical technology cases.